GlobeNewswire

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

Share

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors

LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic.  

ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated.

Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “AXL is a novel and ideal target for an ADC approach, as it is overexpressed in many solid tumor types. We look forward to exploring the effect of ADCT-601 on patients with selected advanced solid tumors who have failed or are intolerant to any established therapy. With five ADCs in eight ongoing clinical trials for multiple indications, we believe our highly targeted therapies have the potential to meaningfully improve outcomes for patients with solid tumors and hematological cancers.”

The open-label, multicenter, single-arm trial will include a Phase Ia dose-escalation part followed by a Phase Ib dose-expansion part. The dose-escalation part is designed to determine the maximum tolerated dose of ADCT-601. The identified dose will be evaluated in the dose-expansion part. Approximately 75 patients will be enrolled in the trial. For more information, please visit www.clinicaltrials.gov (identifier NCT03700294).

About ADCT-601

ADCT-601 is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human AXL, conjugated using GlycoConnect™ technology to a linker with a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell where enzymes release the PBD-based warhead. The PBD-based warhead has the ability to form highly cytotoxic DNA interstrand cross-links, blocking cell division and ultimately killing the cancer cell. ADCT-601 is being evaluated in a Phase I clinical trial in patients with advanced solid tumors (NCT03700294).

About ADC Therapeutics

ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has five PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II, in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.

Investors Contact                                                                       
Dr. Chris Martin                                                                           
Chief Executive Officer                                                                 
Chris.martin@adctherapeutics.com                      
Tel.: +41 (0) 21 653 0200                                  

EU Media Contact
Dynamics Group
amu@dynamicsgroup.ch
Tel: +41 (0) 43 268 3231

USA Media Contact
Tony Plohoros
6 Degrees
tplohoros@6degreespr.com 
Tel.: +1 908-591-2839

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Invitation to Q2 conference call21.8.2019 14:31:00 CESTPress release

Oslo, Norway, 21 August 2019 Vistin Pharma ASA will release its second quarter 2019 results on Thursday 29 August, 2019. Vistin Pharma will host a conference call for all shareholders and interested parties on 29 August at 08:00 CEST. There will be a Q&A session following the management discussion. The second quarter conference call will be available via web and audio through the following access points: Telephone conference: Confirmation Code:........ 9184908 International Dial-In: ..... +44 (0) 2071 928000 Norway, Oslo................. 23960264 United States, New York. 16315107495 Webcast: https://edge.media-server.com/m6/p/cvjpg4fj ***** For further information, please contact: Gunnar Manum CFO +47 95 17 91 90 gunnar.manum@vistin.com

Oboya får en order i Polen21.8.2019 14:29:00 CESTPressemelding

Oboya Horticulture Industries AB (publ) (”Oboya”) har genom sitt helägda dotterbolag VEFI Europa Sp. z o.o i Skierniewice, Polen fått en order på odlingsrännor från befintlig kund i Polen. Ordervärdet uppgår till ca 1,1 MPLN, motsvarande ca 2,7 MSEK. Ordern avser leverans av odlingsrännor till hydroponisk odlingssystem och kommer att levereras löpande under september 2019. Ordervärdet uppgår till 1,1 MPLN, motsvarande ca 2,7 MSEK. Den befintliga kunden F.H. Nowalijka Piotr Wychowałek är ett av de ledande hydroponic odlingsbolag inom sallad och färska örter i Polen. Odlingsrännorna kommer att användas för hydroponisk odling i växthus och odlas utan jord. VEFI grundades 1949 och har varit verksamt i 70 år och är en ledande leverantör av produkter för hydroponisk odlingssystem. Hydroponisk odlingssystem innebär odling i växthus, oberoende av klimat med möjlighet att odla året runt. Odling i hydroponisk odlingssystem sker ofta i ett slutet- och självförsörjande system. Erik Penser Bank AB

Oboya receives an order in Poland21.8.2019 14:29:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya") has through its wholly owned subsidiary VEFI Europa Sp. z o.o in Skierniewice, Poland received an order for cultivation gutter from an existing customer in Poland. The order value amounted to about PLN 1.1 million, corresponding to about SEK 2.7 million. The order concerns delivery of cultivation gutter to hydroponic cultivation systems and will be delivered continuously during September 2019. The order value amounts to PLN 1.1 million, corresponding to approximately SEK 2.7 million. The existing customer F.H. Nowalijka Piotr Wychowałek is one of the leading hydroponic growing companies in lettuce and fresh herbs in Poland. The cultivation gutter will be used for hydroponic cultivation in greenhouses and grown without soil. VEFI was founded in 1949 and has been operating for 70 years and is a leading supplier of products for hydroponic cultivation systems. Hydroponic cultivation system means cultivation in greenhouses, regardless of cli

Conference call 28 August at 10.00 (CEST) about Interim Report Q2 201921.8.2019 13:07:00 CESTPress release

21/08/2019 COMPANY ANNOUNCEMENT 11/2019 Goodvalley will release its Interim Report Q2 2019 on 27 August 2019. On 28 August 2019 at 10.00 (CEST), Goodvalley will host a conference call at which CEO Hans Henrik Pedersen and Vice CEO Kristian Brokop will provide comments on financial and operational performance in Q2 2019, the outlook and answer questions. Registration is not required. The conference call will be conducted in English and can be followed live here: https://edge.media-server.com/mmc/p/vuzfpixi Participants should dial the numbers provided below and state conference code Denmark: +45 32 72 80 42 Norway: +47 239 60264 Sweden: +46 (0)850 692180 Poland +48 222 120 152 United Kingdom: +44 (0)844 571 8892 United States: +1 631 5107495 Further Information Group Communications, Anne Axelgaard + 45 76 52 20 00 investor@goodvalley.com Goodvalley at a glance Goodvalley is an international producer of high quality pork products operating in Poland, Ukraine and Russia based on Danish pr

Rovio Entertainment Corp.: Vodafone and Hatch launch the first premium cloud gaming service in Germany21.8.2019 13:00:00 CESTPress release

Rovio Entertainment Corporation Press Release August 21, 2019 Vodafone and Hatch launch the first premium cloud gaming service in Germany Hatch’s mobile games streaming service now available for Vodafone 5G customers across Germany Available on Android 5G devices, Hatch is optimized for gaming as part of Vodafone’s 5G roll-out Hatch offers Vodafone 5G customers complimentary access to Hatch Premium, which includes unlimited access to more than 100 premium games Vodafone and Hatch, Rovio Entertainment Corp. subsidiary, today announced the launch of the first 5G-optimised cloud gaming service in Germany. Introduced as part of Vodafone Germany’s 5G switch-on, avid and casual gamers alike will be able to stream games instantly from their Android 5G-enabled devices. The Hatch app is now available to download from the Google Play Store. Vodafone 5G customers will have 3-months of complimentary access to Hatch Premium, Hatch’s subscription level plan. After this period, the service will cost

Delårsrapport januari - juni 201921.8.2019 12:10:00 CESTPressemelding

ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 DELÅRSRAPPORT JANUARI – JUNI 2019 Stärkta marginaler ger positiv resultatutveckling Retailsegmentet uppvisar stärkta marginaler vilket påverkar resultatet positivt Integrationen av Em Home belastar enligt plan koncernresultatet med ca 1,8 MSEK första halvåret Samarbetet med Elon inlett, framskrider enligt plan APRIL – JUNI 2019 Nettoomsättningen uppgick till 414,0 (442,1) MSEK. Rörelseresultatet uppgick till 3,0 (2,2) MSEK. Resultat efter skatt uppgick till 2,2 (1,5) MSEK. Resultat per aktie uppgick till 0,41 (0,29) SEK. Kassaflödet från den löpande verksamheten uppgick till -38,3 (-7,7) MSEK. Eget kapital per aktie uppgick till 36,22 (36,05) SEK. JANUARI – JUNI 2019 Nettoomsättningen uppgick till 802,1 (842,6) MSEK. Rörelseresultatet uppgick till 4,8 (4,4) MSEK. Resultat efter skatt uppgick till 3,8 (3,4) MSEK. Resultat per aktie uppgick till 0,72 (0,66) SEK. Kassaflödet från den löpande verksamheten uppgick till -6,6 (13,2) MSEK. Eget kapi